Lupin and Neuclone biosimilars agreement

Biosimilars/News | Posted 10/06/2011 post-comment0 Post your comment

Indian generics manufacturer Lupin Pharmaceuticals has signed an agreement with Australian biotech firm NeuClone to access cell line technology to be used to develop biosimilar drugs targeting cancer.

picture40

The agreement involves transfer of technology, with NeuClone offering an exclusive proprietary mammalian Chinese hamster ovary cell line that will show a specific recombinant protein of interest in oncology to Lupin. This will also mean that scientific research staff from the Lupin Biological Research Programme will work with NeuClone at their facility.

Lupin is aggressively pursuing biosimilars and already has a separate research facility, with about 100 scientists, focused on biotechnology. The company expects in the next five years that 5-7% of its business will come from biosimilars and expects to have its first biosimilar on the market in 2012.

Recent estimates by IMS Health expect the global biosimilars market to exceed US$2 billion annually by 2015 [1], therefore, it is no wonder that most generic manufacturers and many originator companies are taking an interest in this lucrative area of the pharmaceutical market.

Reference

1. GaBI Online - Generics and Biosimilars Initiative. Generics and biosimilars to drive down drug spending [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 June 10]. Available from: www.gabionline.net/Pharma-News/Generics-and-biosimilars-to-drive-down-drug-spending

Source: The Hindu

comment icon Comments (0)
Post your comment
Related content
Clinical trials for aflibercept biosimilars
Clinical trial PainSA V21F04
Biosimilars/News Posted 04/06/2021
Australia approves adalimumab biosimilar Abrilada
Adalimumab 2 V14A10
Biosimilars/News Posted 21/05/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010